Home › Trials › NCT06719440
Clinical trial Recruiting at 18 sites Interventional Ages 18 and up

Limiting the radiation target area for glioblastoma to reduce treatment side effects

Official title: Impact of Reducing the Irradiation Volume on Survival, Toxicity, and Quality of Life in Patients With Glioblastoma Treated With Radiochemotherapy: a Prospective Multicenter Randomised Study

Run by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · NCT06719440 · Data updated 2026-11-12

This trial will test whether giving radiotherapy with a smaller margin around the tumor (10 mm instead of 15 mm) for adults with newly diagnosed glioblastoma can reduce side effects and improve quality of life.

More Glioblastoma trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment347 (estimated)
SponsorCliniques universitaires Saint-Luc- Université Catholique de Louvain
Academic / other
Drugs / interventionschemotherapy, radiation
Locations23 sites (Aalst and 22 other locations)
StatusRecruiting
StartedMay 12, 2025
Main results expectedOctober 2031
Study endsOctober 2031
Registry record updatedFebruary 27, 2026
Trial IDNCT06719440 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) with newly diagnosed, histologically confirmed glioblastoma who are planned for standard chemoradiotherapy and have WHO performance status 0–2 are the intended participants.

Probably not a fit

Patients with recurrent disease, those unable to undergo MRI, those in competing trials, or those not eligible for standard chemoradiotherapy are unlikely to benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial compares two radiotherapy approaches that differ in the clinical target volume margin (10 mm versus 15 mm) delivered with standard concurrent and adjuvant chemotherapy. Adults with newly diagnosed, histologically confirmed glioblastoma and WHO performance status 0–2 are enrolled after multidisciplinary board confirmation. Participants receive one of the two radiotherapy plans and are followed with regular MRI and clinical assessments to record treatment-related toxicity, cognitive effects, quality of life, and tumor control. The goal is to see whether a tighter radiation margin can lower radiation-related side effects without compromising disease control.

Why it matters

Potential benefit: If successful, this approach could lessen radiation-related brain injury and improve patients' quality of life while keeping cancer control similar.

How similar studies have gone: Similar attempts to reduce radiotherapy margins in glioblastoma have been explored before with mixed results, so this approach is still investigational.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participants capable of giving informed consent
* Age \>= 18 y.o.
* WHO performance status 0-2
* Newly diagnosed glioblastoma (Histologically proven glioblastoma per WHO 2021 classification based on biopsy or resection )
* Indication of chemoradiotherapy confirmed by multidisciplinary tumour board

Exclusion Criteria:

* Participation in a competing trial
* Known contraindication to undergo MRI scans

Where it's running

  • EpiCURA
    Baudour, Belgium     Recruiting
  • AZ Sint Jan
    Bruges, Belgium     Recruiting
  • Cliniques universitaires Saint-Luc
    Brussels, Belgium     Recruiting
  • Ziekenhuis Oost-Limburg (ZOL)
    Genk, Belgium     Recruiting
  • AZ Sint-Lucas
    Ghent, Belgium     Recruiting
  • Grand Hôpital de Charleroi
    Gilly, Belgium     Recruiting
Show 17 more locations
  • JESSA Ziekenhuis
    Hasselt, Belgium     Recruiting
  • AZ Groeninge
    Kortrijk, Belgium     Recruiting
  • Chu Helora
    La Louvière, Belgium     Recruiting
  • UZ Leuven
    Leuven, Belgium     Recruiting
  • CHU Liège
    Liège, Belgium     Recruiting
  • AZ Sint Maarten
    Mechelen, Belgium     Recruiting
  • Hôpital André Vésale - HUmani
    Montigny-le-Tilleul, Belgium     Recruiting
  • CHU UCL Namur - Sainte Elisabeth
    Namur, Belgium     Recruiting
  • AZ Delta
    Roeselare, Belgium     Recruiting
  • Cliniques de l'Europe
    Uccle, Belgium     Recruiting
  • CHR Verviers
    Verviers, Belgium     Recruiting
  • ZAS Augustinus
    Wilrijk, Belgium     Recruiting
  • Olv Azorg
    Aalst, Belgium     Not yet recruiting
  • Institut Jules Bordet
    Brussels, Belgium     Not yet recruiting
  • UZ Brussel
    Brussels, Belgium     Not yet recruiting
  • UZ Gent
    Ghent, Belgium     Not yet recruiting
  • CH Mouscron
    Mouscron, Belgium     Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Glioblastoma 622Radiotherapy Side Effect 35Cliniques universitaires Saint-Luc- Université Catholique de Louvain 37
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.